Eisai U.S. Subsidiary To Work With Forma For Drug Discoveries
This article was originally published in PharmAsia News
Eisai's U.S. unit and American drug maker Forma Therapeutics have reached an agreement to collaborate on discovering new compounds
You may also be interested in...
BD and BioMedomics have released a new rapid point-of-care test that can detect antibodies in blood to confirm current or past exposure to COVID-19.
Experts think GLP-1s in neurodegeneration may be Novo Nordisk’s next opportunity and await readouts from the Phase II ELAD trial in Alzheimer's disease for signals.
France has announced a number of emergency measures to protect drug supplies threatened by the spread of the coronavirus.